Ipsen has go/no-go decision to make after biotech partner's Parkinson's drug flunks PhIIb
Swedish biotech IRLAB’s drug may have failed the primary endpoint in a Phase IIb study involving Parkinson’s patients, but execs still believe they have a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
